Dispute over Covid vaccines casts doubt on Clover Bio recovery
The Chinese biopharma firm faces a potentially damaging fight over a $224 million upfront payment it received in an ill-fated deal to supply Covid vaccines Key Takeaways: The Gavi international…
FAST NEWS: AIM Vaccine’s loss balloons
The latest: Vaccine maker AIM Vaccine Co. Ltd. (6660.HK) said on Monday it expects to report a net loss of 1.25 billion yuan ($174 million) to 1.38 billion yuan for last…
FAST NEWS: AIM Vaccine named to MSCI small cap index
The latest: AIM Vaccine Co. Ltd. (6660.HK), China’s second-largest maker of non-Covid vaccines, announced Friday that its shares were selected for inclusion in the MSCI Global Small Cap Index, effective after…
AIM Vaccine Shrinks Its IPO But Gives Chairman a Mega Paycheck
China’s second-largest maker of non-Covid vaccines has finally crossed the IPO finish line and will list its shares next Thursday Key Takeaways: AIM Vaccine is finally landing on the Hong…
AIM Puts mRNA Covid Vaccine in Investor Crosshairs With New IPO Attempt
Vaccine maker’s previous IPO bids on Shenzhen’s ChiNext board and in Hong Kong failed, but it is soldiering ahead with a new attempt in Hong Kong Key takeaways: Vaccine maker AIM…
Everest Joins Race to Make mRNA Covid Vaccines for China
Company’s move comes as Beijing shows growing signs of approving the new type of high-tech vaccination Key takeaways: Everest will pay up to $150 million or more to potentially bring…
